Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00335006 | Liver | NAFLD | carbohydrate homeostasis | 45/1882 | 259/18723 | 1.87e-04 | 3.29e-03 | 45 |
GO:00487327 | Liver | NAFLD | gland development | 67/1882 | 436/18723 | 2.83e-04 | 4.53e-03 | 67 |
GO:00140747 | Liver | NAFLD | response to purine-containing compound | 29/1882 | 148/18723 | 3.34e-04 | 5.13e-03 | 29 |
GO:00450174 | Liver | NAFLD | glycerolipid biosynthetic process | 43/1882 | 252/18723 | 3.83e-04 | 5.73e-03 | 43 |
GO:00468903 | Liver | NAFLD | regulation of lipid biosynthetic process | 32/1882 | 171/18723 | 4.03e-04 | 5.99e-03 | 32 |
GO:00714967 | Liver | NAFLD | cellular response to external stimulus | 51/1882 | 320/18723 | 6.21e-04 | 8.18e-03 | 51 |
GO:0033762 | Liver | NAFLD | response to glucagon | 8/1882 | 21/18723 | 6.29e-04 | 8.21e-03 | 8 |
GO:00075687 | Liver | NAFLD | aging | 53/1882 | 339/18723 | 7.78e-04 | 9.77e-03 | 53 |
GO:00515917 | Liver | NAFLD | response to cAMP | 20/1882 | 93/18723 | 8.01e-04 | 9.95e-03 | 20 |
GO:19016547 | Liver | NAFLD | response to ketone | 34/1882 | 194/18723 | 9.22e-04 | 1.10e-02 | 34 |
GO:00464601 | Liver | NAFLD | neutral lipid biosynthetic process | 13/1882 | 50/18723 | 1.04e-03 | 1.22e-02 | 13 |
GO:00464631 | Liver | NAFLD | acylglycerol biosynthetic process | 13/1882 | 50/18723 | 1.04e-03 | 1.22e-02 | 13 |
GO:00097502 | Liver | NAFLD | response to fructose | 5/1882 | 10/18723 | 1.67e-03 | 1.74e-02 | 5 |
GO:00342847 | Liver | NAFLD | response to monosaccharide | 37/1882 | 225/18723 | 1.86e-03 | 1.91e-02 | 37 |
GO:00097467 | Liver | NAFLD | response to hexose | 36/1882 | 219/18723 | 2.14e-03 | 2.08e-02 | 36 |
GO:00425945 | Liver | NAFLD | response to starvation | 33/1882 | 197/18723 | 2.35e-03 | 2.21e-02 | 33 |
GO:0070741 | Liver | NAFLD | response to interleukin-6 | 12/1882 | 49/18723 | 2.77e-03 | 2.53e-02 | 12 |
GO:1901655 | Liver | NAFLD | cellular response to ketone | 19/1882 | 96/18723 | 2.95e-03 | 2.67e-02 | 19 |
GO:1901617 | Liver | NAFLD | organic hydroxy compound biosynthetic process | 37/1882 | 237/18723 | 4.58e-03 | 3.68e-02 | 37 |
GO:00016786 | Liver | NAFLD | cellular glucose homeostasis | 28/1882 | 172/18723 | 7.15e-03 | 4.96e-02 | 28 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa00620 | Colorectum | AD | Pyruvate metabolism | 28/2092 | 47/8465 | 3.71e-07 | 5.41e-06 | 3.45e-06 | 28 |
hsa00020 | Colorectum | AD | Citrate cycle (TCA cycle) | 20/2092 | 30/8465 | 1.43e-06 | 1.77e-05 | 1.13e-05 | 20 |
hsa00010 | Colorectum | AD | Glycolysis / Gluconeogenesis | 34/2092 | 67/8465 | 3.63e-06 | 4.34e-05 | 2.77e-05 | 34 |
hsa04152 | Colorectum | AD | AMPK signaling pathway | 47/2092 | 121/8465 | 3.74e-04 | 2.82e-03 | 1.80e-03 | 47 |
hsa04922 | Colorectum | AD | Glucagon signaling pathway | 41/2092 | 107/8465 | 1.18e-03 | 7.75e-03 | 4.94e-03 | 41 |
hsa04964 | Colorectum | AD | Proximal tubule bicarbonate reclamation | 11/2092 | 23/8465 | 1.35e-02 | 4.86e-02 | 3.10e-02 | 11 |
hsa006201 | Colorectum | AD | Pyruvate metabolism | 28/2092 | 47/8465 | 3.71e-07 | 5.41e-06 | 3.45e-06 | 28 |
hsa000201 | Colorectum | AD | Citrate cycle (TCA cycle) | 20/2092 | 30/8465 | 1.43e-06 | 1.77e-05 | 1.13e-05 | 20 |
hsa000101 | Colorectum | AD | Glycolysis / Gluconeogenesis | 34/2092 | 67/8465 | 3.63e-06 | 4.34e-05 | 2.77e-05 | 34 |
hsa041521 | Colorectum | AD | AMPK signaling pathway | 47/2092 | 121/8465 | 3.74e-04 | 2.82e-03 | 1.80e-03 | 47 |
hsa049221 | Colorectum | AD | Glucagon signaling pathway | 41/2092 | 107/8465 | 1.18e-03 | 7.75e-03 | 4.94e-03 | 41 |
hsa049641 | Colorectum | AD | Proximal tubule bicarbonate reclamation | 11/2092 | 23/8465 | 1.35e-02 | 4.86e-02 | 3.10e-02 | 11 |
hsa006202 | Colorectum | SER | Pyruvate metabolism | 22/1580 | 47/8465 | 9.62e-06 | 1.33e-04 | 9.67e-05 | 22 |
hsa000202 | Colorectum | SER | Citrate cycle (TCA cycle) | 16/1580 | 30/8465 | 2.06e-05 | 2.74e-04 | 1.99e-04 | 16 |
hsa049222 | Colorectum | SER | Glucagon signaling pathway | 38/1580 | 107/8465 | 2.57e-05 | 3.28e-04 | 2.38e-04 | 38 |
hsa000102 | Colorectum | SER | Glycolysis / Gluconeogenesis | 24/1580 | 67/8465 | 6.62e-04 | 5.36e-03 | 3.89e-03 | 24 |
hsa049642 | Colorectum | SER | Proximal tubule bicarbonate reclamation | 10/1580 | 23/8465 | 5.33e-03 | 3.28e-02 | 2.38e-02 | 10 |
hsa006203 | Colorectum | SER | Pyruvate metabolism | 22/1580 | 47/8465 | 9.62e-06 | 1.33e-04 | 9.67e-05 | 22 |
hsa000203 | Colorectum | SER | Citrate cycle (TCA cycle) | 16/1580 | 30/8465 | 2.06e-05 | 2.74e-04 | 1.99e-04 | 16 |
hsa049223 | Colorectum | SER | Glucagon signaling pathway | 38/1580 | 107/8465 | 2.57e-05 | 3.28e-04 | 2.38e-04 | 38 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PCK1 | SNV | Missense_Mutation | novel | c.85N>A | p.Glu29Lys | p.E29K | P35558 | protein_coding | tolerated(0.59) | benign(0.003) | TCGA-A7-A4SA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
PCK1 | SNV | Missense_Mutation | | c.689C>G | p.Ser230Cys | p.S230C | P35558 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PCK1 | SNV | Missense_Mutation | | c.521N>G | p.Thr174Arg | p.T174R | P35558 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A6IX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PCK1 | SNV | Missense_Mutation | novel | c.369N>T | p.Glu123Asp | p.E123D | P35558 | protein_coding | tolerated(0.57) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PCK1 | SNV | Missense_Mutation | novel | c.1779N>T | p.Glu593Asp | p.E593D | P35558 | protein_coding | tolerated(0.08) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PCK1 | SNV | Missense_Mutation | | c.650C>A | p.Thr217Lys | p.T217K | P35558 | protein_coding | tolerated(0.87) | benign(0.213) | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
PCK1 | SNV | Missense_Mutation | | c.584N>T | p.Ser195Phe | p.S195F | P35558 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-B6-A1KF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PCK1 | SNV | Missense_Mutation | | c.1180N>C | p.Glu394Gln | p.E394Q | P35558 | protein_coding | tolerated(0.26) | benign(0.019) | TCGA-BH-A0HK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
PCK1 | SNV | Missense_Mutation | novel | c.715T>C | p.Ser239Pro | p.S239P | P35558 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-C8-A1HG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PCK1 | SNV | Missense_Mutation | novel | c.971N>T | p.Arg324Met | p.R324M | P35558 | protein_coding | tolerated(0.05) | possibly_damaging(0.904) | TCGA-OL-A97C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |